ZYDENA, an erectile dysfunction treatment independently developed by Dong-A Pharmaceutical, became the
second most prescribed drug of its kind in Korea last year. The industry and pharmaceutical market research
agencies reported on February 25 that ZYDENA carved out a 24.8% market share by volume, nudging Lily Korea’
s CIALIS from the number two position.



With 1,727,532 tablets sold last year, ZYDENA is quickly catching up to VIAGRA, of which 2,979,000 tablets were
sold to account for 42.8% of the market.



Third best-selling CIALIS represented 21.3% of the market in 2008, followed by Chong Kun Dang’s YAILA
(4.3%), Bayer Healthcare’s LEVITRA (3.5%), and SK Chemical’s M-VIX (3.2%).



It is notable that the three multinational products all slid in both sales volume and value, while sales of
ZYDENA rose in both terms, by 22% and 19% respectively.



ZYDENA made its debut in the global market as the fourth of its kind in December 2005. It overtook LEVITRA the
next year as the third best-seller, and easily became the second best-seller in 2008, a mere three years after
its launch.



Last year, the erectile dysfunction treatment market totaled KRW78 billion, up only 0.4% from 2007.



In the mean time, ZYDENA has so far won export agreements worth USD300 million in total, including USD 168
million with Brazil and 15 other South American countries, USD 50 million with Russia, and USD 23 million with
Middle Eastern and North African countries.





Dong-A Pharmaceutical, one of the Korea’s leading research-based pharmaceutical
and healthcare companies, is committed to working for a better tomorrow by following its core value of integrity,
excellence and respect for humanity. Dong-A Pharmaceutical has kept its No. 1 position in the Korean
pharmaceutical market since 1967 with its Zydena(erectile dysfunction treatment), Stillen(gastritis treatment),
Bacchus(refreshing tonic) and other 120 products. For further information, please visit www.donga-pharm.com




Cautionary statement regarding forward-looking statements

Dong-A Pharmaceutical cautions investors that any forward-looking statements or projections made by Dong-A
Pharmaceutical, including those made in this announcement, are subject to risks and uncertainties that may
cause actual results to differ materially from those projected. The forward-looking statements may include
statements regarding product development, product potential or financial performance. No forward-looking
statement can be guaranteed and actual results may differ materially from those projected. Dong-A
Pharmaceutical undertakes no obligation to publicly update any forward-looking statement, whether as a result
of new information, future events, or otherwise.